What Tomorrow Biostasis does

Tomorrow Biostasis GmbH (operating as Tomorrow.bio) is a Berlin-based cryopreservation service provider founded in 2020 by Dr. Emil Kendziorra, a medical doctor and former cancer researcher, and Fernando Azevedo Pinheiro, an industrial engineer and MBA-trained tech executive. The company offers whole-body and brain-only (neuro) cryopreservation of humans and pets using field cryoprotection procedures developed in-house, supported by 24/7 emergency medical standby teams, CT scanning for verification, and indefinite storage at a purpose-built European Biostasis Foundation (EBF) facility in Switzerland using liquid nitrogen at -196°C. The company's core technical differentiator is being the only provider offering whole-body field cryoprotection, avoiding the tissue damage caused by transporting patients before cryopreservation, with all equipment custom-built or sourced from Germany by the Berlin team.

The business model combines a recurring membership subscription (€50/month, €500/year, or €15,000 lifetime) with a deferred one-time procedure fee (€75K–€230K in Europe; $80K–$250K in the US depending on whole-body vs. brain-only and member status). Most members finance the procedure through term life insurance, and the Tomorrow Patient Foundation (TPF) — a companion trust — invests collected funds in low-risk assets targeting a 1–2% real annual return to underwrite perpetual storage costs. As of the source data, the company reports over 1,000 members across 45+ European countries, 20 cryopreserved patients, and 10 cryopreserved pets.

The go-to-market is direct-to-consumer, combining self-service signup and a pricing calculator with consultation-led sales, supported by a multi-channel marketing mix of content marketing, social media, PR (Bloomberg, Washington Post, Forbes, MIT, Sifted), email newsletters, and event sponsorships in the longevity ecosystem. The company launched US operations in July 2024, initially serving New York, California, and Florida, with nationwide expansion planned by mid-2025, representing the principal growth lever.

Name

Tomorrow Biostasis

Legal name

Tomorrow Biostasis GmbH

Website

https://tomorrowbiostasis.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Tomorrow Biostasis provides human and pet cryopreservation services using proprietary whole-body field cryoprotection and indefinite liquid nitrogen storage at a Swiss facility, serving over 1,000 members across 45+ countries.

Ownership category

akta.pro rank

Product category

Cryopreservation Services

NAICS

Death Care Services (8122), Funeral Homes and Funeral Services (812210), Pet Care (except Veterinary) Services (81291)

SIC

Services-Health Services (8000)

akta.pro primary industry

Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK)

akta.pro secondary industries

Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN), Cryogenic Logistics (LN2 Dry Shippers, -150°C) (HLAGAMAB), Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ), Cryopreservation, Biobanking & Cell Banking (Cord/Adipose/MSC) (HLAMANAJ), Hospice & Palliative Respite Care (HSABAGAG)

Keywords

• Human cryopreservation
• Cryonics services
• Biostasis technology
• Pet cryopreservation
• Cryogenic storage

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Membership fees: Recurring membership fees providing 24/7 medical standby, equipment maintenance, welcome box, community access, priority support, and exclusive member events. Fee is paid during member's lifetime.
2. Cryopreservation procedure fees: One-time fees covering the entire cryopreservation process including team dispatch, standby until legal pronouncement of death, cryopreservation procedure, transportation to Switzerland, and indefinite storage. Fee is paid at time of death.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Tomorrow Biostasis provides human and pet cryopreservation services through a field cryoprotection procedure that preserves patients immediately upon legal pronouncement of death, avoiding tissue damage from transport. The offering includes whole-body and brain-only cryopreservation, 24/7 emergency medical standby with dispatch teams, transport to a purpose-built Swiss storage facility, and indefinite liquid nitrogen storage. A subscription membership program provides ongoing standby coverage and reduced procedure fees.

Product overview

Tomorrow.bio operates as a cryopreservation service provider offering a comprehensive suite of services centered on human and pet cryopreservation. The core offering includes whole-body and brain-only (neuro) cryopreservation with field cryoprotection procedures, supported by 24/7 emergency medical standby services. The company maintains patients indefinitely at its European Biostasis Foundation (EBF) facility in Switzerland using liquid nitrogen storage. Membership programs provide reduced pricing and ongoing support, while the Tomorrow Patient Foundation (TPF) ensures long-term financial stability through managed investments. Additional services include pet cryopreservation, life extension advisory sessions, and a finance calculator for pricing estimates.

Differentiator

Problem solved

Functional benefit

Products and services

• Whole-Body Human Cryopreservation Complete whole-body cryopreservation at -196°C using proprietary field cryoprotection and vitrification techniques with cryoprotectant solutions to prevent ice crystal formation. Includes 24/7 medical team dispatch, standby until legal pronouncement of death, cryopreservation procedure, transport to Switzerland, and indefinite liquid nitrogen storage. Available for €200,000 (members) or €230,000 (non-members) in Europe and $220,000 (members) or $250,000 (non-members) in the US.
• Brain-Only (Neuro) Cryopreservation Isolated brain cryopreservation focusing on preserving neural structures and the connectome for potential future revival and rejuvenation. Includes medical standby, procedure, transport to Swiss facility, and indefinite storage. Available for €75,000 (members) or €115,000 (non-members) in Europe and $80,000 (members) or $110,000 (non-members) in the US.
• Pet Cryopreservation Cryopreservation services for pets, allowing pet owners to preserve their companion animals for potential future revival technology. 10 pets have been cryopreserved by Tomorrow Biostasis.
• Long-Term Cryogenic Storage Indefinite patient storage at the European Biostasis Foundation facility in Switzerland, maintained with liquid nitrogen at -196°C with no electricity required. Purpose-built facility leveraging Swiss security, stability, and rule of law.
• Membership Program Subscription program providing 24/7 medical standby, equipment maintenance, welcome box, community access, priority support, and exclusive member events. Lowers cryopreservation procedure costs for members. Available at €50/month, €500/year, or €15,000 lifetime in Europe ($55/month, $550/year, or $15,000 lifetime in US).
• Emergency Medical Standby 24/7 availability of medical teams for immediate dispatch upon legal pronouncement of death, including ambulances and heart-lung machines for field cryoprotection procedures.
• Life Extension Advisory Optimized 1-on-1 sessions aimed at maximizing human life limits through longevity-focused guidance, available through a waitlist.

Quantifiable outcome

• Cryopreservation maintained indefinitely without degradation at -196°C in liquid nitrogen
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• European Biostasis Foundation (EBF)coreStrategic or Co-development Partner · 1 March 2026EBF operates the Swiss long-term storage facility where all Tomorrow Biostasis patients are preserved indefinitely. EBF is the companion organization responsible for cryopreservation storage operations.
• Tomorrow Patient Foundation (TPF)coreStrategic or Co-development Partner · 1 March 2026TPF is a patient care trust that manages cryopreservation funds. It invests in very low-risk investments yielding 1-2% annual return above inflation to cover ongoing maintenance costs indefinitely.
• SoTAminorStrategic or Co-development Partner · 1 March 2026Co-organizer of the London Longevity Network's 'Defeating Entropy' hackathon focused on organ replacement and biostasis.
• London Longevity NetworkminorStrategic or Co-development Partner · 1 March 2026London-based longevity network co-organizing the 'Defeating Entropy' event with Tomorrow Biostasis backing.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• BioLife Solutions: BioLife Solutions is a US biopreservation company supplying cryopreservation media, storage products, and cold-chain technology to the cell and gene therapy market. It is not a direct competitor but is a relevant adjacent incumbent in the broader cryopreservation tools and consumables ecosystem.
• Cryoport: Cryoport is a publicly traded US company providing cryogenic logistics and cold-chain solutions primarily for life sciences and reproductive medicine. While not a direct cryonics competitor, it operates in the same cryogenic logistics technology category that underpins Tomorrow Biostasis's transport operations.

Direct peers

• KrioRus: KrioRus is a Russian cryonics provider founded in 2005, offering whole-body and neuro cryopreservation with storage facilities in Russia. It is one of the few operational European-region peers alongside Tomorrow Biostasis and serves a comparable transnational cryopreservation customer base.
• Cryonics Institute: Cryonics Institute is a Michigan-based, member-funded cryopreservation provider founded in 1976, offering lower-cost whole-body cryopreservation. It competes directly with Tomorrow Biostasis in the same human cryopreservation category, particularly on price-sensitive members globally.
• Alcor Life Extension Foundation: Alcor is the largest and longest-standing US cryonics organization, founded in 1972 and based in Scottsdale, Arizona. It offers whole-body and neuro cryopreservation with long-term patient storage, making it the closest direct competitor to Tomorrow Biostasis in services, customer profile, and business model.

Emerging players

• Oregon Cryonics: Oregon Cryonics is a small US Pacific Northwest provider offering whole-body cryopreservation on a smaller scale. It competes in the same category as Tomorrow Biostasis but with limited geographic reach, making it an emerging rather than scaled peer.
• Southern Cryonics: Southern Cryonics is an Australia-based emerging cryopreservation organization building out its first dedicated storage facility. It targets the same end-customer segment as Tomorrow Biostasis (life-extension individuals) but serves a different geography and is at an earlier operational stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/tomorrowbio
• YouTubeyoutube.com/@TomorrowBio
• Facebookfacebook.com/tomorrowbiostasis
• LinkedInlinkedin.com/company/tomorrow-biostasis
• Instagraminstagram.com/tomorrowbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tomorrow Biostasis